safety – Medxy AI

Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials

By MedXY 09/04/2026

This review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vaccination strategy against invasive meningococcal disease in adolescents and young adults.

Diabetes & Endocrinology news

Long-term Safety of Oral Orforglipron in Japanese Patients with Type 2 Diabetes (ACHIEVE-J): A Multicenter, Randomized, Open-label, Phase 3 Trial

By MedXY 08/18/2026

This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.

Diabetes & Endocrinology news Oncology

Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents

By MedXY 06/28/2026

Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control rate.

news Public Health Respiratory

Electronic Cigarettes for Smoking Cessation: An Updated Review

By MedXY 12/18/2025

This review examines the safety and effectiveness of electronic cigarettes as aids to quit smoking, showing increased abstinence rates compared to traditional therapies and no significant serious adverse events reported.

Infectious Diseases news Pediatrics

Single low‑dose primaquine (0.25 mg/kg) is safe and effective for blocking Plasmodium falciparum transmission in children and adults

By MedXY 11/23/2025

A pooled individual‑patient meta‑analysis (6056 participants) shows single low‑dose primaquine (0.25 mg/kg) added to ACTs reduces gametocyte carriage and mosquito infectivity across ages and transmission settings without increasing clinically important haemolysis.

Infectious Diseases news Public Health

rVSVΔG‑LASV‑GPC Lassa Vaccine Shows Broad Immunogenicity and Acceptable Safety in Phase 1 Trial

By MedXY 11/10/2025

A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages.

Clinical Updates news Public Health

Effectiveness and Safety of RSV Vaccination in US Adults Aged 60 Years or Older: A Comprehensive Evidence Synthesis

By MedXY 10/31/2025

RSV vaccines demonstrate substantial effectiveness and acceptable safety profiles in adults aged ≥60, with diminished effectiveness in immunocompromised subgroups and a low, statistically significant increased risk of Guillain-Barré syndrome for certain formulations.

news Psychiatry

Assessing Nearly Five Years of Real-World Safety Data on Esketamine Nasal Spray in the United States

By MedXY 10/30/2025

A comprehensive evaluation of nearly five years of esketamine nasal spray use confirms its safety profile consistent with clinical trials, with no new safety signals detected in over 1.4 million treatment sessions.

Critical Care Emergency Medicine news

Reassessing the Safety of Peripheral Vasopressor Use in Early Sepsis: Evidence from a Large Prospective Cohort Study

By MedXY 10/27/2025

This study evaluates factors influencing vasopressor route choice in sepsis and demonstrates low complication rates associated with peripheral administration, supporting its safety in early resuscitation.

Hematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Clinical Updates news Oncology

Innovative DEP-SN38 Nanoparticle Delivery Shows Promise in Advanced Solid Tumors: Safety and Preliminary Efficacy Unveiled

By MedXY 09/20/2025

This phase I study demonstrates that DEP-SN38, a dendrimer-nanoparticle conjugate of SN38, is well tolerated with minimal gastrointestinal toxicity and shows encouraging antitumor activity in heavily pretreated advanced solid tumors.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Epaminurad: A Promising hURAT1 Inhibitor for Effective and Safe Gout Management – Insights from a Phase 2b Dose-Finding Trial

By MedXY 08/26/2025

Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12 weeks.

Clinical Updates Dermatology news Specialties

Low-Dose Oral Minoxidil: Safe from Tachycardia Risk in Large Alopecia Cohort

By MedXY 08/19/2025

A large retrospective study of over 524,000 patients found no increased risk of tachycardia associated with low-dose oral minoxidil (≤5 mg/day) for nonscarring hair loss, supporting its cardiac safety profile in patients without preexisting cardiac conditions.

Clinical Updates Neurology Specialties

Mechanical Thrombectomy in Distal Medium MCA Occlusion: Impact of Pre-Stroke Low-Dose Aspirin on Efficacy and Safety

By MedXY 08/17/2025

Pre-stroke low-dose aspirin in distal medium vessel occlusion stroke patients undergoing mechanical thrombectomy is linked to improved 90-day functional outcomes and reduced mortality without increased symptomatic hemorrhage risk.

Clinical Updates Neurology news Specialties

Edaravone Dexborneol in Acute Ischemic Stroke: Real-World Evidence of Enhanced Functional Recovery and Safety

By MedXY 08/17/2025

In a large multicenter cohort study, edaravone dexborneol treatment in acute ischemic stroke patients was linked to improved 90-day functional outcomes without increased adverse events, supporting its clinical utility.

Gastroenterology news Specialties

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis

By MedXY 08/14/2025

Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.

Clinical Updates Infectious Diseases Public Health Specialties

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

By MedXY 08/03/2025

MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.

Medical News news

Benzene in Acne Products: Clinical Implications, Risks, and Regulatory Response

By MedXY 07/31/2025

Recent findings of benzene in benzoyl peroxide acne products have sparked debate, recalls, and regulatory scrutiny, prompting calls for improved safety measures despite the continued clinical utility of these therapies.